Correlation of ultrasound attenuation imaging versus MRI proton density fat fraction in non-alcoholic fatty liver


  • Pantajaree Hiranrat, M.Sc. Sonographer school, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand.
  • Surachate Siripongsakun, M.D Sonographer School,HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand.
  • Kamonwan Soonklang, M.Sc. Data Management Unit, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand.



Attenuation Imaging, Fatty liver, Steatosis, MRI-PDFF, MRE, NAFLD


Background: Attenuation Imaging (ATI) is a novel method for assessment of hepatic steatosis, based on ultrasound attenuation by calculating attenuation coefficient which increases in the fatty liver condition. The previous published data comparing ATI and Magnetic Resonance Proton Density Fat Fraction (MR-PDFF) has moderate to high correlation coefficient (r=0.66-0.81). However, fatty liver is commonly associated with obesity which may be an influencing factor of the ATI measurement.


Objective: The purpose of this study was to evaluate diagnostic accuracy of ATI in non-alcoholic fatty liver disease (NAFLD) compared to MRI-PDFF


Materials and Methods: The 62 non-alcoholic fatty liver disease (NAFLD) patients with available ATI, MRI-PDFF, and MRE examination, excluding cirrhosis, history of significant alcohol drinking, and chronic liver condition were retrospectively evaluated.


Results: The correlation coefficient (r) of ATI vs MRI-PDFF were in good correlation (r = 0.63-0.69, p<0.001). The inter-observer reliability of two observers was 100% with the Cohen kappa coefficient of 1.00 (p < 0.001).Area under the receiver operating characteristics of ATI for diagnosis of steatosis grade > 0 was 0.96 and for diagnosis of steatosis grade > 1 was 0.83.


Conclusions: ATI is a novel ultrasound method to quantify the degree of fat deposition with a good correlation to MRI-PDFF with high interobserver’ reliability. Obesity commonly associated with fatty liver may be an interfering factor of ATI measurement.


Download data is not yet available.


Metrics Loading ...


Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84. doi: 10.1002/hep.28431.

Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis 2016;20:205-14. doi: 10.1016/j.cld.2015.10.001.

Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:511-31. doi: 10.1016/j.cld.2009.07.005.

Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004;16:1087-93. doi: 10.1097/00042737-200411000-00002.

Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000;45:1929-34. doi: 10.1023/a:1005661516165.

Wu KT, Kuo PL, Su SB, Chen YY, Yeh ML, Huang CI, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol 2016;10:420-5 e1. doi: 10.1016/j.jacl.2015.12.026.

Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:1212-8. doi: 10.2337/dc06-2247.

Ajmera V, Park CC, Caussy C, Singh S, Hernandez C, Bettencourt R, et al. Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2018;155:307-10 e2. doi: 10.1053/j.gastro.2018.04.014.

Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective. Expert Rev Gastroenterol Hepatol 2011;5:223-31. doi: 10.1586/egh.11.8.

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009;49:1017-44. doi: 10.1002/hep.22742.

Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 2014;34:102-9. doi: 10.1111/liv.12282.

Cassidy FH, Yokoo T, Aganovic L, Hanna RF, Bydder M, Middleton MS, et al. Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics 2009;29:231-60. doi: 10.1148/rg.291075123.

Middleton MS, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, et al. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. Gastroenterology 2017;153:753-61. doi: 10.1053/j.gastro.2017.06.005.

Le TA, Chen J, Changchien C, Peterson MR, Kono Y, Patton H, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012;56:922-32. doi: 10.1002/hep.25731.

Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol 2016;65:369-76. doi: 10.1016/j.jhep.2016.04.021.

Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol 2018;10:530-42. doi: 10.4254/wjh.v10.i8.530.

Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006;239:105-12. doi: 10.1148/radiol.2391050361.

Lee HW, Park SY, Kim SU, Jang JY, Park H, Kim JK, et al. Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. PLoS One 2016;11:e0157358. doi: 10.1371/journal.pone.0157358.

Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010;36:1825-35. doi: 10.1016/j.ultrasmedbio.2010.07.005.

Vuppalanchi R, Siddiqui MS, Van Natta ML, Hallinan E, Brandman D, Kowdley K, et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 2018;67:134-44. doi: 10.1002/hep.29489.

Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F, et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997;27:108-13. doi: 10.1016/s0168-8278(97)80288-7.

Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006;38:485-9. doi: 10.1016/j.dld.2006.03.021.

Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50. doi: 10.1053/gast.2002.35354.

Shannon A, Alkhouri N, Carter-Kent C, Monti L, Devito R, Lopez R, et al. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr 2011;53:190-5. doi: 10.1097/MPG.0b013e31821b4b61.

Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol 2014;20:10851-63. doi: 10.3748/wjg.v20.i31.10851.

Tada T, Iijima H, Kobayashi N, Yoshida M, Nishimura T, Kumada T, et al. Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic Steatosis. Ultrasound Med Biol 2019;45:2679-87. doi: 10.1016/j.ultrasmedbio.2019.05.033.

Jeon SK, Lee JM, Joo I, Yoon JH, Lee DH, Lee JY, et al. Prospective Evaluation of Hepatic Steatosis Using Ultrasound Attenuation Imaging in Patients with Chronic Liver Disease with Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard. Ultrasound Med Biol 2019;45:1407-16. doi: 10.1016/j.ultrasmedbio.2019.02.008.

Bae JS, Lee DH, Lee JY, Kim H, Yu SJ, Lee JH, et al. Assessment of hepatic steatosis by using attenuation imaging: a quantitative, easy-to-perform ultrasound technique. Eur Radiol 2019;29:6499-507. doi: 10.1007/s00330-019-06272-y.

Ferraioli G, Maiocchi L, Raciti MV, Tinelli C, De Silvestri A, Nichetti M, et al. Detection of Liver Steatosis With a Novel Ultrasound-Based Technique: A Pilot Study Using MRI-Derived Proton Density Fat Fraction as the Gold Standard. Clin Transl Gastroenterol 2019;10:e00081. doi: 10.14309/ctg.0000000000000081.

Caussy C, Alquiraish MH, Nguyen P, Hernandez C, Cepin S, Fortney LE, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology 2018;67:1348-59. doi: 10.1002/hep.29639.

Hoodeshenas S, Yin M, Venkatesh SK. Magnetic Resonance Elastography of Liver: Current Update. Top Magn Reson Imaging 2018;27:319-33. doi: 10.1097/RMR.0000000000000177.

Colton T. Statistics in Medicine. Boston: Little, Brown and Company; 1974.

Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5. doi: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>;2-3.

McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 2012;22:276-82.

Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. Hepatology 2018;68:763-72. doi: 10.1002/hep.29797.

Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012;36:22-9. doi: 10.1111/j.1365-2036.2012.05121.x.

Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13-5. doi: 10.1136/bmj.292.6512.13.

Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;102:2708-15. doi: 10.1111/j.1572-0241.2007.01526.x.

Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol 2005;5:14. doi: 10.1186/1471-230X-5-14.

Mathiesen UL, Franzen LE, Aselius H, Resjo M, Jacobsson L, Foberg U, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002;34:516-22. doi: 10.1016/s1590-8658(02)80111-6.

Soresi M, Giannitrapani L, Florena AM, La Spada E, Di Gesaro V, Rappa F, et al. Reliability of the bright liver echo pattern in diagnosing steatosis in patients with cryptogenic and HCV-related hypertransaminasaemia. Clin Radiol 2009;64:1181-7. doi: 10.1016/j.crad.2009.06.013.

Culjat MO, Goldenberg D, Tewari P, Singh RS. A review of tissue substitutes for ultrasound imaging. Ultrasound Med Biol 2010;36:861-73. doi: 10.1016/j.ultrasmedbio.2010.02.012.

Ferraioli G, Maiocchi L, Savietto G, Tinelli C, Nichetti M, Rondanelli M, et al. Performance of the Attenuation Imaging Technology in the Detection of Liver Steatosis. J Ultrasound Med 2021;40:1325-32. doi: 10.1002/jum.15512.

Yoo J, Lee JM, Joo I, Lee DH, Yoon JH, Kang HJ, et al. Reproducibility of ultrasound attenuation imaging for the noninvasive evaluation of hepatic steatosis. Ultrasonography 2020;39:121-9. doi: 10.14366/usg.19034.

Kremkau FW. Sonography: Principles and Instruments. 9th ed. Philadelphia: Elsevier; 2016.




How to Cite

Hiranrat P, Siripongsakun S, Soonklang K. Correlation of ultrasound attenuation imaging versus MRI proton density fat fraction in non-alcoholic fatty liver. ASEAN J Radiol [Internet]. 2022Dec.31 [cited 2023Feb.9];23(3):184-205. Available from:



Original Article